Current Edition


Polyphor announces enrollment of first patient in Phase III clinical trial for murepavadin – a pathogen-specific antibiotic being developed for the treatment of nosocomial pneumonia

Potentially first new class of antibiotics in Phase III development against Gramnegative pathogens in 50 years Polyphor today announced the enrollment of the first patient …

Continue Reading →